Australian Diabetes Society
Baseline blood work before starting the combination should include a comprehensive metabolic panel covering sodium, potassium, chloride, bicarbonate, BUN, creatinine, and glucose
Optimizing outcomes for GLP-1 agonists
However, beyond the efficacy for metabolic control, the current guidelines of diabetes mellitus pharmacotherapy are directed towards protection in the cardiovascular health and other complications, for which this pharmacological group is positioned as an important option, demonstrating a reduction of cardiovascular events compared to placebo which may be comparable to recent result from SGLT-2 inhibitors
It is investigated in experimental models for its interaction with growth factor signaling, angiogenesis-related mechanisms, and cytoprotective processes